

February 13, 2013

**The Manager
Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor, Plot No: C/1
G - Block, Bandra - Kurla Complex
Bandra (East), Mumbai – 400 051**

Dear Sirs,

Sub: Unaudited Financial Results for the Quarter/Nine months ended 31th December, 2012

In accordance with the Clause 41 of the listing agreement, we are enclosing the following


- ❖ Copy of the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2012 along with the press release in this respect.
- ❖ Copy of the limited review report on the aforesaid Unaudited Financial Results as issued by the Statutory Auditors of the Company.

The above Unaudited Financial Results and the limited review report have been taken on record by the Board of Directors at their meeting held on February 13, 2013.

This is for your information and records.

Thanking you,

Yours faithfully,


L Chandrasekar

Executive V P – Finance & Secretary

Encl.: a/a

BSE: 524372 NSE: ORCHIDCHEM Bloomberg: OCP@IN Reuters: ORCD.BO

Q3 FY13 Earnings

Chennai, India – February 13, 2013

Orchid Pharma registers turnover of Rs 322 crore in Q3 FY13

Financial highlights for Quarter ended December 31, 2012 (Q3 FY13)

Earnings on consolidated basis

- Revenue of Rs 322 crore (US\$ 58.5 million) in Q3 FY13 versus Rs 496.8 crore (US\$ 90.3 million) in Q3 FY12
- EBITDA of Rs 21.6 crore (US\$ 3.9 million) in Q3 FY13 versus Rs 129.0 crore (US\$ 23.5 million) in Q3 FY12
- Loss before Tax of Rs 88.7 crore (US\$ 16.1 million) in Q3 FY13 compared to a profit before tax of Rs 41.1 crore (US\$ 7.5 million) during Q3 FY12
- At the net level, the company registered a loss (after exceptional item loss of Rs 5.6 crore) of Rs 74.7 crore (US\$ 13.6 million) in Q3 FY13 compared to a loss of Rs 11.06 crore (US\$ 2.0 million) during Q3 FY12

Financial highlights for 9-mths ended December 31, 2012

Earnings on consolidated basis

- Revenue of Rs 1107.1 crore (US\$ 201.3 million) in the 9-months ended December 31, 2012 versus Rs 1411.8 crore (US\$ 256.7 million) in the corresponding period of last fiscal
- EBITDA of Rs 113.1 crore (US\$ 20.6 million) in the 9-months ended December 31, 2012 versus Rs 324.1 crore (US\$ 58.9 million) in the same period of last fiscal
- Loss before Tax (before exceptional item loss of Rs 20.8 crore / extraordinary item gain of Rs 53.3 crore) of Rs 227.6 crore (US\$ 41.4 million) in the 9-months ended December 31, 2012 compared to a profit before tax of Rs 91.9 crore (US\$ 16.7 million) during the corresponding period of last fiscal
- Net loss after Tax (after exceptional item loss of Rs 20.8 crore / extraordinary item gain of Rs 53.3 crore) of Rs 152.7 crore (US\$ 27.8 million) in the 9-months ended December 31, 2012 compared to a net profit of Rs 82.2 crore (US\$ 14.9 million) registered during the same period last fiscal

‘Orchid Towers’, #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA




From the Chairman & Managing Director

"The overall performance of the company continues to witness pressure due to the tight working capital levels and debt leverage. We are working on completing the transfer of our Penicillin & Carbapenem business to Hospira and will see a significantly deleveraged position from the deal proceeds leading to improved performance in the quarters to come", said Mr K Raghavendra Rao, Chairman & Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.

* 1 US\$ = Rs 55

**For ORCHID CHEMICALS &
PHARMACEUTICALS LTD.**


Chairman & Managing Director

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA